Editorial: Tumor Heterogeneity and Personalized Medicine — NEJM

Blogger's Note: this Editorial requires a subscription ($$$)

Editorial

Tumor Heterogeneity and Personalized Medicine

This article has no abstract; the first 100 words appear below.

"In the past 10 years, the number of tools available to treat cancer has increased, as has our understanding of what makes some cancers tick. The standard old-time cancer treatments were largely predicated on attacking DNA, an approach fueled by the belief that tumor cells divide more rapidly than normal cells. However, with the notable exception of Burkitt's lymphoma, only a small percentage of tumor cells in a patient are dividing at any given time. As we have learned more about DNA repair mechanisms and epigenetic alterations in cancers, DNA remains a viable target for new cancer therapies, but DNA . . ."

Editorial: The heterogeneity of epithelial ovarian cancer. Getting it right David M. Gershenson

Editorial
The heterogeneity of epithelial ovarian cancer
Getting it right

David M. Gershenson, MD *
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
email: David M. Gershenson (DGERSHEN@mdanderson.org)

Abstract
Epithelial ovarian cancer is heterogeneous and comprises 4 major rare subtypes - mucinous, clear cell, low-grade serous, and endometrioid - all distinct from the more common high-grade serous carcinoma. Women with uncommon histotypes should be triaged to separate clinical trials.